Adicet Bio Inc Sustainability Reports
Adicet Bio, Inc. is a clinical-stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies. The company engineers these therapies with chimeric antigen receptors (CARs) to target cancer and autoimmune diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300VRD2QO80WBOP18
2 reports from 2020 to 2024
Company Profile
Adicet Bio, Inc. is a clinical-stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies. The company engineers these therapies with chimeric antigen receptors (CARs) to target cancer and autoimmune diseases.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
